NCT05745090View on ClinicalTrials.gov

N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) in Type 2 Diabetes Mellitus

Active, not recruitingOBSERVATIONAL
Enrollment

1,200

Participants

Timeline

Start Date

November 10, 2022

Primary Completion Date

March 31, 2029

Study Completion Date

April 30, 2029

Conditions
Type2diabetesHeart FailureCardiovascular Complication
Trial Locations (1)

Unknown

Singapore General Hospital, Singapore

All Listed Sponsors
collaborator

Roche Diagnostics GmbH

INDUSTRY

lead

Singapore General Hospital

OTHER